Sign in or Register   Sign in or Register
  |  

Mouse Anti-TMEM230 Recombinant Antibody (3B2) (CBMAB-C5703-LY)

This product is antibody recognizes TMEM230. The antibody 3B2 immunoassay techniques such as: IHC-F, WB.
See all TMEM230 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
3B2
Antibody Isotype
IgG2a
Application
IHC-F, WB

Basic Information

Immunogen
Full length human recombinant protein of human C20orf30(NP_054864) produced in HEK293T cell
Specificity
Human
Antibody Isotype
IgG2a
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Concentration
1.75 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Transmembrane Protein 230
Introduction
This gene encodes a multi-pass transmembrane protein that belongs to the TMEM134/TMEM230 protein family. The encoded protein localizes to secretory and recycling vesicle in the neuron and may be involved in synaptic vesicles trafficking and recycling. Mutations in this gene may be linked to familial Parkinson's disease. [provided by RefSeq, Mar 2017]
Entrez Gene ID
29058
UniProt ID
Q96A57
Alternative Names
Transmembrane Protein 230; C20orf30; UPF0414 Transmembrane Protein C20orf30; Chromosome 20 Open Reading Frame 30; DJ1116H23.2.1; HSPC274;
Function
Involved in trafficking and recycling of synaptic vesicles.
Biological Process
Synaptic vesicle transport
Cellular Location
Membrane
Golgi apparatus, trans-Golgi network
Cytoplasmic vesicle, secretory vesicle, synaptic vesicle
Early endosome
Recycling endosome
Late endosome
Cytoplasmic vesicle, autophagosome
Involvement in disease
Parkinson disease (PARK):
A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-TMEM230 Recombinant Antibody (3B2)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare